Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Primary prophylactic pegfilgrastim in small cell lung cancer receiving chemo-immunotherapy (pilot study)
jRCT1061240128Recruiting
- Start
- Mar 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of pegfilgrastim in small cell lung cancer (SCLC). Primary endpoint: Ratio of cases with febrile neutropenia. Started Mar 2025; status: recruiting.
02
Drugs
pegfilgrastim
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCT1061240128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1061240128.